Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

COMy 2019 | What is the future for myeloma clinical trials?

Mohamad Mohty • 17 May 2019
COMy 2019
Multiple Myeloma

Mohamad Mohty, MD, PhD of Saint-Antoine Hospital, Paris, France, discusses the future of clinical trials for multiple myeloma, including a focus on smoldering myeloma and stopping the evolution of myeloma at an earlier stage, rather than after organ damage. This interview took place at the Controversies in Multiple Myeloma (COMy) 2019 World Congress in Paris, France.

More from Mohamad Mohty

Advances in GvHD management presented at ASH 2025 5:07
Advances in GvHD management presented at ASH 2025
Mohamad Mohty • 5 Dec 2025
Myeloma updates from EHA 2022: the DETERMINATION trial, the role of transplant, and exciting novel immunotherapies
Mohamad Mohty et al. • 15 Jul 2022
Optimizing conditioning regimens for SCT in AML and MDS 3:38
Optimizing conditioning regimens for SCT in AML and MDS
Mohamad Mohty • 31 Mar 2025
Optimizing anti-CD38 monoclonal antibody-based quadruplet therapies in newly diagnosed myeloma 4:28
Optimizing anti-CD38 monoclonal antibody-based quadruplet therapies in newly diagnosed myeloma
Mohamad Mohty • 31 Mar 2025

Related Videos

Integrating molecular diagnostics in smoldering myeloma to predict disease progression 1:37
Integrating molecular diagnostics in smoldering myeloma to predict disease progression
Gareth Morgan • 7 Dec 2025
Prolonged elranatamab treatment interruption in R/R myeloma: MagnetisMM-3 retrospective analysis 2:35
Prolonged elranatamab treatment interruption in R/R myeloma: MagnetisMM-3 retrospective analysis
Alexander Lesokhin • 8 Dec 2025
Integrated approaches to improve prognosis prediction in multiple myeloma 2:32
Integrated approaches to improve prognosis prediction in multiple myeloma
Claudio Cerchione • 6 Dec 2025
The iMMunoPET trial: 89Zr-DFO-daratumumab for CD38-targeted imaging of multiple myeloma 4:45
The iMMunoPET trial: 89Zr-DFO-daratumumab for CD38-targeted imaging of multiple myeloma
Ola Landgren • 6 Dec 2025
The content of VJHemOnc is intended for healthcare professionals